Detail akcie Avicanna Rg Reg S online

Business Summary: Avicanna Inc. is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. It has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Avicanna Inc revenues increased less than 1% to C$18.9M. Net loss decreased 46% to C$2M. Revenues reflect License Revenue increase of 100% to C$1.3M, Service Revenue increase of 18% to C$1.1M, also reflect Product Sales decrease of 5% to C$16.4M. Lower net loss reflects General and administrative - Balancing v decrease of 20% to C$2.6M (expense).